INTRODUCING ANZUPGO—the first and only FDA-approved treatment for adults with moderate-to-severe Chronic Hand Eczema (CHE)1,2
For more information on the FDA approval, see the press release.
What is Chronic Hand Eczema (CHE)?
CHE is defined as hand eczema that lasts more than 3 months
or has returned 2x or more within a year.4
It's a multifactorial, heterogeneous, relapsing disease that's more than just atopic dermatitis (AD).2,4
AD can be a contributing factor alongside irritant and allergic contact dermatitis, which can all overlap.2,4
Itch and pain are the most debilitating symptoms, but CHE can have an array of clinical presentations.2,4,5
Skin clearance data1,3
Effective across all CHE subtypes1,6*
Significant clearance at Weeks 4, 8, and 16 vs cream vehicle1,3
DELTA 1: ANZUPGO (N=325) vs cream vehicle (N=162)
- Week 4: 15.4% vs 4.9%; P=0.0007
- Week 8: 22.8% vs 10.5%; P=0.001
- Week 16: 19.7% vs 9.9%; P=0.0055
DELTA 2: ANZUPGO (N=313) vs cream vehicle (N=159)
- Week 4: 14.7% vs 8.2%; P=0.043
- Week 8: 32.3% vs 9.4%; P<0.0001
- Week 16: 29.1% vs 6.9%; P<0.0001
Itch and pain relief data1
Significant improvement in itch and pain at Weeks 2 and 4, respectively, vs cream vehicle
DELTA 1: ANZUPGO vs cream vehicle
- Itch reduction, Week 2 (N=323 vs 161): 15.5% vs 6.2%; P=0.0037
- Pain reduction, Week 4 (N=291 vs 149): 34.4% vs 14.8%; P<0.0001
DELTA 2: ANZUPGO vs cream vehicle
- Itch reduction, Week 2 (N=309 vs 156): 12.9% vs 6.4%; P=0.031
- Pain reduction, Week 4 (N=294 vs 141): 31.0% vs 10.6%; P<0.0001
Favorable safety profile, comparable to cream vehicle1
In the Prescribing Information:
No boxed warning
No known drug-drug interactions†
No contraindications
No required routine lab monitoring
Adverse reactions that were reported in ≤1% of DELTA 1 and DELTA 2 subjects from the ANZUPGO group included1
- Application site pain, paresthesia, pruritus, erythema, and bacterial skin infections, including finger cellulitis, paronychia, other skin infections, leukopenia, and neutropenia
*The primary classifications of CHE by subtype were atopic hand eczema (35.9%), hyperkeratotic eczema (21.5%), irritant contact dermatitis (19.6%), allergic contact dermatitis (13.9%), vesicular hand eczema (9.1%), and contact urticaria/protein contact dermatitis (0.1%). Across all trial arms, 28% of subjects were diagnosed with two or more overlapping CHE subtypes.1
†Conducted in in-vitro studies.
FORMULATED FOR
HANDS that need to get UP & GO
- A steroid-free, non-greasy cream1
- No added absorption enhancers1
- No sensitizers or irritants known to commonly trigger CHE1,7,8
Study Design: randomized, multicenter, double-blind, vehicle-controlled, 16-week trials in 960 adults with moderate-to-severe, uncontrolled CHE.1 Primary endpoint: IGA-CHE treatment success at Week 16, defined as a score of 0 (clear) or 1 (almost clear) with at least a 2-point improvement from baseline.1
Key secondary endpoints: ≥4-point reduction in HESD-itch and -pain at various time points during the 16-week treatment period.1
HESD=Hand Eczema Symptom Diary (an 11-point rating scale designed to measure the 6 CHE signs and symptoms over the past 24 hours); IGA-CHE=Investigator's Global Assessment for Chronic Hand Eczema (a 5-point assessment scale: 4, severe; 3, moderate; 2, mild; 1, almost clear; 0, clear).1,3
Alexandra K. Golant, MD
Brad P. Glick, DO, MPH
Joseph Gorelick, MSN, FNP-BC
Leon H. Kircik, MD
Raj Chovatiya, MD, PhD, MSCI
See below for a list of available sessions
This educational program is sponsored by LEO Pharma Inc. No CME/CE credit will be provided. In accordance with PhRMA Guidelines, only physicians and healthcare professionals involved in providing patient care or product recommendations may attend this informative program. Attendance by guests or spouses is not permitted. No alcohol is provided at this program. This invitation is intended for the recipient only and is non-transferable.
Please note: Your name and the value of any meal/refreshment will be reported as required by federal and state laws. You have the option to decline the meal by informing the LEO Pharma representative upon sign-in and LEO Pharma will not report a transfer of value to you. If you are licensed in Minnesota or Vermont you are not eligible to receive meals provided during this event under state law. Please notify the LEO Pharma representative during sign-in. US Government employees may also be subject to rules that prevent or limit the provision of meals. We ask that US Government employees comply with these rules.
Please note: Your name and the value of any meal/refreshment will be reported as required by federal and state laws. You have the option to decline the meal by informing the LEO Pharma representative upon sign-in and LEO Pharma will not report a transfer of value to you. If you are licensed in Minnesota or Vermont you are not eligible to receive meals provided during this event under state law. Please notify the LEO Pharma representative during sign-in. US Government employees may also be subject to rules that prevent or limit the provision of meals. We ask that US Government employees comply with these rules.
Want to learn more?
